These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 5925687)

  • 21. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
    Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT
    Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy during pregnancy: when and how? Particulars in gynecologic and breast cancers].
    Giacalone PL; Bénos P; Charlier C; Laffargue F
    J Gynecol Obstet Biol Reprod (Paris); 1997; 26(3 Suppl):197-200. PubMed ID: 9471460
    [No Abstract]   [Full Text] [Related]  

  • 24. First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer.
    Ardavanis A; Tryfonopoulos D; Orphanos G; Ioannidis G; Karamouzis M; Rigatos G
    Anticancer Res; 2005; 25(6C):4493-8. PubMed ID: 16334132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
    Chang YC; Falkson G; Tormey DC; Crowley J
    Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
    Jurga L; Misurová E; Vancík J
    Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
    [No Abstract]   [Full Text] [Related]  

  • 27. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
    Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
    Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
    Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
    Feng J; Zheng X; Dai A
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):468-70. PubMed ID: 10920949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer].
    Takayama T; Nomura Y
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):73-80. PubMed ID: 10660736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages].
    Pannuti F; Di Marco AR; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
    Minerva Ginecol; 1982 Nov; 34(11):977-9. PubMed ID: 7155427
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 35. [The thyroid hormone as complementary treatment in genital and mammary cancer].
    da Silveira JC
    Rev Ginecol Obstet (Sao Paulo); 1965 Jun; 116(6):287-93. PubMed ID: 5897927
    [No Abstract]   [Full Text] [Related]  

  • 36. [On methods of prolonged intra-arterial chemotherapy of malignant neoplasms of the genitalia].
    Persianinov LS; Gasparian NN; Gasparian SA
    Akush Ginekol (Mosk); 1966 Apr; 42(4):3-9. PubMed ID: 5987801
    [No Abstract]   [Full Text] [Related]  

  • 37. [Synthetic progestatives in the treatment of hormono-dependent cancers in gynecology].
    Albeaux-Fernet M; Bellot L; Canet L; Deribreux J; Gelinet M
    Annee Endocrinol; 1970; 22():141-51. PubMed ID: 5485064
    [No Abstract]   [Full Text] [Related]  

  • 38. [Proceedings: Testing of gynecologic neoplasms in tissue culture against cytostatics and hormones with special reference to breast carcinomas].
    Stoldt H; Wolf J; Buchhold G
    Arch Gynakol; 1975 Nov; 219(1-4):185-6. PubMed ID: 1243284
    [No Abstract]   [Full Text] [Related]  

  • 39. [Endolymphatic therapy].
    Thepot JY
    Bull Mem Soc Chir Paris; 1971; 61(6):369-76. PubMed ID: 5152094
    [No Abstract]   [Full Text] [Related]  

  • 40. [A study of the effect of endoxan on the serum cholinesterase activity in gynecologic carcinomas].
    Dacić Z
    Zentralbl Gynakol; 1965 Sep; 87(37):1249-56. PubMed ID: 5884968
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.